Novartis (NVS) stock news

PepGen soars on promising early data for muscular dystrophy drug

While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.

6 dividend stocks for investors who want to cut their exposure to the S&P 500

Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.

Companies promised AI gains — here's how the payoff showed up in earnings

Santander, Novartis and other companies say AI is beginning to boost revenue, cut costs or improve profitability as investors seek returns.

Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

A pharma giant is moving past one patent cliff — but another is already looming

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.

Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.

Novartis ends Fabhalta trial for lupus kidney disease